Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 4/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.35 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927181 | 0.67 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CSLC9A1 | |
| SCHEMBL927564 | 0.65 | KDM4E (0.38) | ADRA2AADRA2BADRA2CSLC9A1 | |
| SCHEMBL2085329 | 0.62 | ADRA2A (0.47) | ADRA2AADRA2BADRA2C | |
| SCHEMBL3993813 | 0.62 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CSLC9A1 | |
| SCHEMBL25060963 | 0.61 | ADRA2A (0.42) | ADRA2AADRA2BADRA2C | |
| SCHEMBL18248744 | 0.61 | ADRA2A (0.54) | ADRA2AADRA2BADRA2CSLC9A1 | |
| SCHEMBL20877646 | 0.61 | ADRA2A (0.42) | ADRA2AADRA2BADRA2C | |
| SCHEMBL20877621 | 0.61 | ADRA2A (0.42) | ADRA2AADRA2BADRA2C | |
| SCHEMBL29649376 | 0.61 | ADRA2A (0.54) | ADRA2AADRA2BADRA2CSLC9A1 | |
| SCHEMBL19817529 | 0.61 | ADRA2A (0.42) | ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1849774-B1 | CYCLOHEPTA(b)PYRIDINE-3-CARBONYLGUANIDINE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | TOA EIYO LTD (JP) | 2011-06-29 | — | — | EP | disclosed |
| US-7875625-B2 | 3-guanidinocarbonyl-2-methyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ylmethyl hydrogen sulfate, inhibitory effect on an Na+/H+ exchanger; | TOA EIYO LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| US-20090012114-A1 | Cyclohepta[B]Pyridine-3-Carbonylguanidine Derivative and Pharmaceutical Product Containing Same | TOA EIYO LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012114-A1 | Cyclohepta[B]Pyridine-3-Carbonylguanidine Derivative and Pharmaceutical Product Containing Same | SLC10A6, SLC26A3, SLC9A3 | ADRA2A 350/4885ADRA2B 252/4885ADRA2C 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.